Development of promiR-29 to Prevent Hypertrophic Scarring

Project: Research project

Project Details


The objective of this project is to investigate the efficacy of promiR-29 as a new pharmacologic agent to prevent hypertrophic scarring after cutaneous injury. Our hypothesis is that administration of miR-29 following wound re-epithelialization will prevent the deposition or accumulation of collagen and other extracellular matrix proteins and thereby prevent scarring. miR-29 may therefore improve patient outcomes following trauma, burns or surgery, without compromising the ability to achieve wound closure.
Effective start/end date11/25/135/24/14


  • miRagen Therapeutics, Inc. (Agmt 11/25/13)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.